These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 28232470)

  • 21. Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice.
    Taniguchi T; Asano Y; Akamata K; Noda S; Takahashi T; Ichimura Y; Toyama T; Trojanowska M; Sato S
    Arthritis Rheumatol; 2015 Feb; 67(2):517-26. PubMed ID: 25385187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A possible contribution of endothelial CCN1 downregulation due to Fli1 deficiency to the development of digital ulcers in systemic sclerosis.
    Saigusa R; Asano Y; Taniguchi T; Yamashita T; Takahashi T; Ichimura Y; Toyama T; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
    Exp Dermatol; 2015 Feb; 24(2):127-32. PubMed ID: 25421497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1.
    Bujor AM; Haines P; Padilla C; Christmann RB; Junie M; Sampaio-Barros PD; Lafyatis R; Trojanowska M
    Int J Mol Med; 2012 Dec; 30(6):1473-80. PubMed ID: 23041765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosis.
    Akamata K; Asano Y; Taniguchi T; Yamashita T; Saigusa R; Nakamura K; Noda S; Aozasa N; Toyama T; Takahashi T; Ichimura Y; Sumida H; Tada Y; Sugaya M; Kadono T; Sato S
    Rheumatology (Oxford); 2015 Jul; 54(7):1308-16. PubMed ID: 25539827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A possible contribution of lipocalin-2 to the development of dermal fibrosis, pulmonary vascular involvement and renal dysfunction in systemic sclerosis.
    Takahashi T; Asano Y; Noda S; Aozasa N; Akamata K; Taniguchi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Tada Y; Sugaya M; Kadono T; Sato S
    Br J Dermatol; 2015 Sep; 173(3):681-9. PubMed ID: 25781362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double heterozygous mice for Klf5 and Fli1 genes: a new animal model of systemic sclerosis recapitulating its three cardinal pathological features.
    Asano Y
    Med Mol Morphol; 2015 Sep; 48(3):123-8. PubMed ID: 25986681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis.
    Noda S; Asano Y; Takahashi T; Akamata K; Aozasa N; Taniguchi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Yanaba K; Tada Y; Sugaya M; Kadono T; Sato S
    Rheumatology (Oxford); 2013 May; 52(5):790-9. PubMed ID: 23287360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The
    Kavian N; Mehlal S; Jeljeli M; Saidu NEB; Nicco C; Cerles O; Chouzenoux S; Cauvet A; Camus C; Ait-Djoudi M; Chéreau C; Kerdine-Römer S; Allanore Y; Batteux F
    Front Immunol; 2018; 9():1896. PubMed ID: 30177933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of functional (GA)n microsatellite polymorphism in the FLI1 gene with susceptibility to human systemic sclerosis.
    Yamashita K; Kawasaki A; Matsushita T; Furukawa H; Kondo Y; Okiyama N; Nagaoka S; Shimada K; Sugii S; Katayama M; Hirohata S; Okamoto A; Chiba N; Suematsu E; Setoguchi K; Migita K; Sumida T; Tohma S; Hamaguchi Y; Hasegawa M; Sato S; Kawaguchi Y; Takehara K; Tsuchiya N
    Rheumatology (Oxford); 2020 Nov; 59(11):3553-3562. PubMed ID: 32696043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progranulin overproduction due to constitutively activated c-Abl/PKC-δ/Fli1 pathway contributes to the resistance of dermal fibroblasts to the anti-fibrotic effect of tumor necrosis factor-α in localized scleroderma.
    Miyagawa T; Ichimura Y; Nakamura K; Hirabayashi M; Yamashita T; Saigusa R; Miura S; Takahashi T; Toyama T; Taniguchi T; Akamata K; Yoshizaki A; Sato S; Asano Y
    J Dermatol Sci; 2018 Nov; 92(2):207-214. PubMed ID: 30268392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A possible implication of reduced levels of LIF, LIFR, and gp130 in vasculopathy related to systemic sclerosis.
    Taniguchi T; Miyagawa T; Tamaki Z; Nakamura K; Yamashita T; Saigusa R; Takahashi T; Toyama T; Ichimura Y; Yoshizaki A; Tada Y; Sugaya M; Kadono T; Sato S; Asano Y
    Arch Dermatol Res; 2017 Dec; 309(10):833-842. PubMed ID: 29038846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Inflammation in Animal Models of Systemic Sclerosis.
    Yamashita T; Asano Y; Taniguchi T; Nakamura K; Saigusa R; Miura S; Toyama T; Takahashi T; Ichimura Y; Yoshizaki A; Trojanowska M; Sato S
    J Invest Dermatol; 2017 Mar; 137(3):631-640. PubMed ID: 27777101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts.
    Wang Y; Fan PS; Kahaleh B
    Arthritis Rheum; 2006 Jul; 54(7):2271-9. PubMed ID: 16802366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis.
    Noda S; Asano Y; Akamata K; Aozasa N; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Yanaba K; Tada Y; Sugaya M; Kadono T; Sato S
    PLoS One; 2012; 7(2):e32272. PubMed ID: 22384200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endothelial CCR6 expression due to FLI1 deficiency contributes to vasculopathy associated with systemic sclerosis.
    Ikawa T; Miyagawa T; Fukui Y; Toyama S; Omatsu J; Awaji K; Norimatsu Y; Watanabe Y; Yoshizaki A; Sato S; Asano Y
    Arthritis Res Ther; 2021 Nov; 23(1):283. PubMed ID: 34774095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum S100A12 levels: Possible association with skin sclerosis and interstitial lung disease in systemic sclerosis.
    Omatsu J; Saigusa R; Miyagawa T; Fukui Y; Toyama S; Awaji K; Ikawa T; Norimatsu Y; Yoshizaki A; Sato S; Asano Y
    Exp Dermatol; 2021 Mar; 30(3):409-415. PubMed ID: 33068321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin.
    Kubo M; Czuwara-Ladykowska J; Moussa O; Markiewicz M; Smith E; Silver RM; Jablonska S; Blaszczyk M; Watson DK; Trojanowska M
    Am J Pathol; 2003 Aug; 163(2):571-81. PubMed ID: 12875977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fli1 deficiency induces endothelial adipsin expression, contributing to the onset of pulmonary arterial hypertension in systemic sclerosis.
    Miyagawa T; Taniguchi T; Saigusa R; Fukayama M; Takahashi T; Yamashita T; Hirabayashi M; Miura S; Nakamura K; Yoshizaki A; Sato S; Asano Y
    Rheumatology (Oxford); 2020 Aug; 59(8):2005-2015. PubMed ID: 31782787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Contribution of LIGHT (TNFSF14) to the Development of Systemic Sclerosis by Modulating IL-6 and T Helper Type 1 Chemokine Expression in Dermal Fibroblasts.
    Ikawa T; Ichimura Y; Miyagawa T; Fukui Y; Toyama S; Omatsu J; Awaji K; Norimatsu Y; Watanabe Y; Yoshizaki A; Sato S; Asano Y
    J Invest Dermatol; 2022 Jun; 142(6):1541-1551.e3. PubMed ID: 34838790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis.
    Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Dermatol Sci; 2005 Jul; 39(1):1-7. PubMed ID: 15885984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.